Consumers's Willingness to Pay for Avoiding Salmonella Infection

Salmonellosis is a widely known infectious disease in Hungary that played dominant role between 1960 and 1996 and remained one of the top food-borne illnesses to these days with an estimated total number of 96 048 cases (2019). Beside direct costs of treatment, indirect costs are also significant on the level of population. Among indirect costs, consumer well-being losses are difficult to be estimated. For this purpose, the willingness to pay (WTP) method is used most frequently that measures the cost an individual would undertake to avoid a certain harm. For the well-being loss estimation, the data of National Food Chain Safety Authority's annual consumer survey was used, in which 323 respondents gave evaluable answer to the open-ended WTP question. Results indicate that an average respondent would pay 18.6 EUR to avoid salmonellosis. Main factors affecting WTP were size of family and number of children. The numbers indicate that the consumer well-being loss could be about 1 786 060 EUR annually, resulting from the multiplication of the estimated number of annual salmonellosis cases and the average WTP value. It can be concluded that consumer well-being losses alone would call for further interventions in Salmonella eradication, not to mention other – more direct – cost elements

Overview of cattle diseases listed under category C, D or E in the animal health law for wich control programmes are in place within Europe

13 páginas, 5 figuras, 3 tablas.The COST action “Standardising output-based surveillance to control non-regulated diseases of cattle in the European Union (SOUND control),” aims to harmonise the results of surveillance and control programmes (CPs) for non-EU regulated cattle diseases to facilitate safe trade and improve overall control of cattle infectious diseases. In this paper we aimed to provide an overview on the diversity of control for these diseases in Europe. A non-EU regulated cattle disease was defined as an infectious disease of cattle with no or limited control at EU level, which is not included in the European Union Animal health law Categories A or B under Commission Implementing Regulation (EU) 2020/2002. A CP was defined as surveillance and/or intervention strategies designed to lower the incidence, prevalence, mortality or prove freedom from a specific disease in a region or country. Passive surveillance, and active surveillance of breeding bulls under Council Directive 88/407/EEC were not considered as CPs. A questionnaire was designed to obtain country-specific information about CPs for each disease. Animal health experts from 33 European countries completed the questionnaire. Overall, there are 23 diseases for which a CP exists in one or more of the countries studied. The diseases for which CPs exist in the highest number of countries are enzootic bovine leukosis, bluetongue, infectious bovine rhinotracheitis, bovine viral diarrhoea and anthrax (CPs reported by between 16 and 31 countries). Every participating country has on average, 6 CPs (min–max: 1–13) in place. Most programmes are implemented at a national level (86%) and are applied to both dairy and non-dairy cattle (75%). Approximately one-third of the CPs are voluntary, and the funding structure is divided between government and private resources. Countries that have eradicated diseases like enzootic bovine leukosis, bluetongue, infectious bovine rhinotracheitis and bovine viral diarrhoea have implemented CPs for other diseases to further improve the health status of cattle in their country. The control of non-EU regulated cattle diseases is very heterogenous in Europe. Therefore, the standardising of the outputs of these programmes to enable comparison represents a challenge.Peer reviewe

Analysis of the Target Group of Lactose-Free Functional Foods for Product Development

The aim of this research was to assess the consumer habits of lactose sensitive persons in case of lactose-free products and their other shopping aspects for development of new, dairy-based lactose-free products. The research was based on face-to-face questionnaire survey, and those who declared to be lactose sensitive were analysed. Among them, only half of the women (49.3%) and one third of the men (34.6%) were medically proven lactose sensitive, so more than half of the respondents declared themselves affected on the basis of self-diagnosis. Our results show that reliably regular customers of lactose-free products are women and persons with medical diagnosis, high educational degree, and under the age of 30. The lactose-free consumer group prefers the following product features: lactose-free label; rich in calcium, vitamins, and fibre, and free of carbohydrate, sugar, and gluten. Only two-thirds of lactose sensitive customers (66.7%) consume lactose-free products regularly, so it can be assumed that the level of knowledge of this disease, its treatment, and the importance of lactose-free dairy products among these persons is insufficient. This could be solved with education, advertisement, and other information opportunities

The incidence of mastitis treated with antibiotics in large-scale Hungarian Holstein-Friesian dairy farms

Treated mastitis episodes at large Hungarian dairy farms were studied to determine the distribution of mastitis treated with antibiotics among quarters of the udder. Data were detailed records of all mastitis episodes that occurred during 1976 lactations in Farm A infected with Staphylococcus aureus (from May 1995 through July 1998) and 808 lactations in Farm B free from S. aureus (from January 1999 through March 2001). The distribution of treated quarters was compared with mathematical expectations based upon a random distribution in the case of Farm A. Results on mastitis incidences for different lactation stage groups showed an increasing incidence within subsequent lactation stage groups in Farm A. In contrast, in Farm B the mastitis incidence for lactation stage group between 35 and 100 days was the highest, but beyond 100 days the incidence decreased and reached the lowest value. Results gave strong evidence that the four quarters within the udder are not distributed randomly with respect to naturally occurring episodes of treated mastitis. More episodes than expected occurred in which only one or all four quarters were treated. Fewer episodes than expected with two or three treated quarters were observed. In both farms, the mastitis rate for rear quarters was higher than for front quarters, and the incidence of right quarter mastitis episodes was higher than that of left quarter mastitis episodes

Expression of claudin-1 in canine peripheral nerve sheath tumours and perivascular wall tumours. Immunohistochemical study

Aims: A peripheral nerve sheath tumour consists of neoplastic Schwann cells or perineurial cells, or a mixture of Schwann cells, perineurial cells and fibroblasts. The first aim of the present study was to characterise the expression of the claudin-1 tight junction protein in canine intact peripheral nerves, canine benign peripheral nerve sheath tumours (cBPNSTs), such as schwannomas, neurofibromas, perineuriomas and canine malignant peripheral nerve sheath tumours (cMPNSTs), and in different other benign and malignant canine spindle cell tumours. The second aim of the present study was to examine whether claudin-1 can help to distinguish the subgroups of canine perivascular wall tumours. Methods and results: The biopsy and necropsy samples (n=203) included 10 intact peripheral nerves, 20 cBPNSTs (4 schwannomas, 8 neurofibromas, 8 perineuriomas), 16 cMPNSTs, 6 psammomatous meningiomas, 6 dermatofibromas, 6 leiomyomas, 6 myxomas, 4 spindle cell hemangiomas, 2 spindle cell lipomas, 6 fibrohistiocytic nodules, 8 fibrosarcomas, 8 leiomyosarcomas, 6 myxosarcomas, 8 hemangiosarcomas, 8 anaplastic sarcomas, 8 amelanotic spindle cell melanomas, 8 histiocytic sarcomas, 8 spindle cell carcinomas, 8 myoepitheliomas, 8 complex carcinomas, 5 cardiac rhabdomyosarcomas, 4 synovial sarcomas, 5 osteosarcomas, 4 chondrosarcomas and 4 liposarcomas; 31 canine perivascular wall tumours: 10 hemangiopericytomas, 8 myopericytomas, 6 angioleiomyomas, 4 angioleiomyosarcomas, 3 angiofibromas. The immunohistochemical panel consisted of humanized antibodies: anti-claudin-1, anti-neuron specific enolase, anti-S-100 protein, anti-α-smooth muscle actin, anti-vimentin, anti-cytokeratin AE1-AE3, anti-claudin-5, anti-Melan-A and anti-heavy caldesmon, anti-calponin and anti-desmin. The intact perineurial cells, all perineuriomas, neurofibromas, cMPNSTs, spindle cell carcinomas and epithelial components of the complex carcinomas, all hemangiopericytomas and myo-pericytomas showed claudin-1 positivity. The schwannomas and other spindle shape cell tumours were negative for claudin-1. Conclusion: Our findings suggest that an antibody against claudin-1, in combination with other antibodies, can be used as a novel diagnostic tool to differentiate canine peripheral nerve sheath tumours from other fusocellular tumours, and anti-claudin-1, together with other antibodies, can also be used to subclassify cBPNSTs. Furthermore, analysis of claudin-1 expression can help to differentiate between subgroups of canine perivascular wall tumour

The influence of laterality on mastitis incidence in dairy cattle - preliminary study

During summer (June to August) of continental weather conditions treated mastitis episodes at a large Hungarian dairy farm were studied to determine the relationship between the distribution of mastitis among quarters of the udder and the lying behaviour (laterality) of the cows. There was a significant difference in laterality between cows that developed mastitis and cows that did not. Cows that developed mastitis, had an increased left laterality in lying, which was related to the increased probability of a right-sided mastitis episode. However, the effect was not significant due to the large variation in the data. At the same time, significantly more cows with clinical mastitis had a somatic cell count (SCC) higher than that of cows without clinical mastitis. While a significant correlation was found between the occurrence of treated mastitis cases and SCC ≯ 1,000,000, no statistically significant differences could be observed in milk production between the two groups

Curcumin and Its Analogue Induce Apoptosis in Leukemia Cells and Have Additive Effects with Bortezomib in Cellular and Xenograft Models

Combination therapy of bortezomib with other chemotherapeutics is an emerging treatment strategy. Since both curcumin and bortezomib inhibit NF-κB, we tested the effects of their combination on leukemia cells. To improve potency, a novel Mannich-type curcumin derivative, C-150, was synthesized. Curcumin and its analogue showed potent antiproliferative and apoptotic effects on the human leukemia cell line, HL60, with different potency but similar additive properties with bortezomib. Additive antiproliferative effects were correlated well with LPS-induced NF-κB inhibition results. Gene expression data on cell cycle and apoptosis related genes, obtained by high-throughput QPCR, showed that curcumin and its analogue act through similar signaling pathways. In correlation with in vitro results similar additive effect could be obsereved in SCID mice inoculated systemically with HL60 cells. C-150 in a liposomal formulation given intravenously in combination with bortezomib was more efficient than either of the drugs alone. As our novel curcumin analogue exerted anticancer effects in leukemic cells at submicromolar concentration in vitro and at 3 mg/kg dose in vivo, which was potentiated by bortezomib, it holds a great promise as a future therapeutic agent in the treatment of leukemia alone or in combination